Pub Date : 1998-11-01DOI: 10.1093/rheumatology/37.11.1177
M Turunen, P Kuusisto, P E Uggeldahl, A Toivanen
Objective: To characterize the clinical picture of Pogosta disease.
Method: The data of 73 patients who had had Pogosta disease in 1981 and who then had been seen by a local physician in North Karelia were analysed.
Results: The main manifestations were fever (23%), rash (88%) and joint symptoms (93%). The joint symptoms in some patients lasted for several months and were severe enough to cause immobilization. The clinical picture was identical in those patients who had a definite serological diagnosis and those who did not have a detectable antibody response.
Conclusion: The symptoms of Sindbis virus-induced Pogosta discase consist of fever, rash and joint symptoms, whic may be severe and prolonged.
{"title":"Pogosta disease: clinical observations during an outbreak in the province of North Karelia, Finland.","authors":"M Turunen, P Kuusisto, P E Uggeldahl, A Toivanen","doi":"10.1093/rheumatology/37.11.1177","DOIUrl":"https://doi.org/10.1093/rheumatology/37.11.1177","url":null,"abstract":"<p><strong>Objective: </strong>To characterize the clinical picture of Pogosta disease.</p><p><strong>Method: </strong>The data of 73 patients who had had Pogosta disease in 1981 and who then had been seen by a local physician in North Karelia were analysed.</p><p><strong>Results: </strong>The main manifestations were fever (23%), rash (88%) and joint symptoms (93%). The joint symptoms in some patients lasted for several months and were severe enough to cause immobilization. The clinical picture was identical in those patients who had a definite serological diagnosis and those who did not have a detectable antibody response.</p><p><strong>Conclusion: </strong>The symptoms of Sindbis virus-induced Pogosta discase consist of fever, rash and joint symptoms, whic may be severe and prolonged.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 11","pages":"1177-80"},"PeriodicalIF":0.0,"publicationDate":"1998-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.11.1177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20760213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/RHEUMATOLOGY/37.10.1110
H. Häuselmann, M. Caravatti, B. Seifert, K. Wang, P. Bruckner, G. Stucki, B. Michel
OBJECTIVE Based on the results of two recently published, randomized, double-blind and placebo-controlled studies, a possible improvement in rheumatoid arthritis disease activity after oral tolerization with triple helical collagen type II has been suggested. The goal of this study was to go one step further and ask the question whether collagen type II can sustain the therapeutic effect induced by methotrexate, the most widely accepted disease-modifying anti-rheumatic drug in patients with long-standing rheumatoid arthritis. METHODS Ninety-two patients with rheumatoid arthritis on stable therapy with methotrexate were enrolled in a 3 month double-blind, randomized and comparative study to examine the efficacy of oral triple helical collagen type II as compared to continuing methotrexate. The dose of methotrexate (or the respective placebo drug) and of concomitant corticosteroids was not changed and intra-articular corticosteroids were not allowed during the 3 months. The primary study endpoint was disease activity as measured by physician and patients. RESULTS While patients under ongoing therapy with methotrexate had, as expected, no change in disease activity, almost all parameters of disease activity and outcome in patients under a daily oral dose of 0.5 mg triple helical collagen type II worsened significantly (highly significant difference in swollen joints, between the two groups, P < 0.0001). No significant differences in side-effects between the two groups during the study period could be demonstrated. CONCLUSIONS Substitution of methotrexate with daily 0.5 mg of triple helical collagen type II in patients with rheumatoid arthritis leads to a significant increase in disease activity, suggesting that oral collagen type II at the given dose is not capable of sustaining the methotrexate-induced anti-inflammatory effect in patients with long-standing rheumatoid arthritis.
{"title":"Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial.","authors":"H. Häuselmann, M. Caravatti, B. Seifert, K. Wang, P. Bruckner, G. Stucki, B. Michel","doi":"10.1093/RHEUMATOLOGY/37.10.1110","DOIUrl":"https://doi.org/10.1093/RHEUMATOLOGY/37.10.1110","url":null,"abstract":"OBJECTIVE\u0000Based on the results of two recently published, randomized, double-blind and placebo-controlled studies, a possible improvement in rheumatoid arthritis disease activity after oral tolerization with triple helical collagen type II has been suggested. The goal of this study was to go one step further and ask the question whether collagen type II can sustain the therapeutic effect induced by methotrexate, the most widely accepted disease-modifying anti-rheumatic drug in patients with long-standing rheumatoid arthritis.\u0000\u0000\u0000METHODS\u0000Ninety-two patients with rheumatoid arthritis on stable therapy with methotrexate were enrolled in a 3 month double-blind, randomized and comparative study to examine the efficacy of oral triple helical collagen type II as compared to continuing methotrexate. The dose of methotrexate (or the respective placebo drug) and of concomitant corticosteroids was not changed and intra-articular corticosteroids were not allowed during the 3 months. The primary study endpoint was disease activity as measured by physician and patients.\u0000\u0000\u0000RESULTS\u0000While patients under ongoing therapy with methotrexate had, as expected, no change in disease activity, almost all parameters of disease activity and outcome in patients under a daily oral dose of 0.5 mg triple helical collagen type II worsened significantly (highly significant difference in swollen joints, between the two groups, P < 0.0001). No significant differences in side-effects between the two groups during the study period could be demonstrated.\u0000\u0000\u0000CONCLUSIONS\u0000Substitution of methotrexate with daily 0.5 mg of triple helical collagen type II in patients with rheumatoid arthritis leads to a significant increase in disease activity, suggesting that oral collagen type II at the given dose is not capable of sustaining the methotrexate-induced anti-inflammatory effect in patients with long-standing rheumatoid arthritis.","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"378 1","pages":"1110-7"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75861259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1102
A C Verhoeven, J C Bibo, M Boers, G L Engel, S van der Linden
Objective: Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone.
Methods: Multicentre 56 week randomized double-blind trial with full economic analysis of direct costs and utility analysis with rating scale and standard gamble measurement techniques.
Results: The combined-treatment group included 76 patients and the sulphasalazine group 78 patients. The mean total costs per patient in the first 56 weeks of follow-up were $5519 for combined treatment and $6511 for treatment with sulphasalazine alone (P = 0.37). Out-patient care, in-patient care and non-health care each contributed about one-third to the total costs. The combined-treatment group appeared to generate savings in the length of hospital stay for RA, non-protocol drugs and costs of home help, but comparisons were not statistically significant. Protocol drugs and monitoring were slightly more expensive in the combined-treatment group. Clinical, radiographic and functional outcomes significantly favoured combined treatment at week 28 (radiography also at week 56). Utility scores also favoured combined treatment.
Conclusion: Combined treatment is cost-effective due to enhanced efficacy at lower or equal direct costs.
{"title":"Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis.","authors":"A C Verhoeven, J C Bibo, M Boers, G L Engel, S van der Linden","doi":"10.1093/rheumatology/37.10.1102","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1102","url":null,"abstract":"<p><strong>Objective: </strong>Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone.</p><p><strong>Methods: </strong>Multicentre 56 week randomized double-blind trial with full economic analysis of direct costs and utility analysis with rating scale and standard gamble measurement techniques.</p><p><strong>Results: </strong>The combined-treatment group included 76 patients and the sulphasalazine group 78 patients. The mean total costs per patient in the first 56 weeks of follow-up were $5519 for combined treatment and $6511 for treatment with sulphasalazine alone (P = 0.37). Out-patient care, in-patient care and non-health care each contributed about one-third to the total costs. The combined-treatment group appeared to generate savings in the length of hospital stay for RA, non-protocol drugs and costs of home help, but comparisons were not statistically significant. Protocol drugs and monitoring were slightly more expensive in the combined-treatment group. Clinical, radiographic and functional outcomes significantly favoured combined treatment at week 28 (radiography also at week 56). Utility scores also favoured combined treatment.</p><p><strong>Conclusion: </strong>Combined treatment is cost-effective due to enhanced efficacy at lower or equal direct costs.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1102-9"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1118
J David, S Modi, A A Aluko, C Robertshaw, J Farebrother
Objective: To evaluate the effectiveness of acupuncture, as compared with physiotherapy, in the management of chronic neck pain.
Design: Seventy adult patients with non-inflammatory neck pain of >6 weeks duration and with no abnormal neurology were randomly assigned to receive either of the treatments. Thirty-five patients were included in each group.
Outcome measures: Pain by visual analogue scale and neck pain questionnaire, improvement in range of movement of neck relative to baseline, and well-being (general health questionnaire). Measurements were recorded at the start of treatment, at 6 weeks and at 6 months.
Results: Both treatment groups improved in all criteria. Acupuncture was slightly more effective in patients who had higher baseline pain scores.
Conclusions: Both acupuncture and physiotherapy are effective forms of treatment. Since an untreated control group was not part of the study design, the magnitude of this improvement cannot be quantified.
{"title":"Chronic neck pain: a comparison of acupuncture treatment and physiotherapy.","authors":"J David, S Modi, A A Aluko, C Robertshaw, J Farebrother","doi":"10.1093/rheumatology/37.10.1118","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1118","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of acupuncture, as compared with physiotherapy, in the management of chronic neck pain.</p><p><strong>Design: </strong>Seventy adult patients with non-inflammatory neck pain of >6 weeks duration and with no abnormal neurology were randomly assigned to receive either of the treatments. Thirty-five patients were included in each group.</p><p><strong>Outcome measures: </strong>Pain by visual analogue scale and neck pain questionnaire, improvement in range of movement of neck relative to baseline, and well-being (general health questionnaire). Measurements were recorded at the start of treatment, at 6 weeks and at 6 months.</p><p><strong>Results: </strong>Both treatment groups improved in all criteria. Acupuncture was slightly more effective in patients who had higher baseline pain scores.</p><p><strong>Conclusions: </strong>Both acupuncture and physiotherapy are effective forms of treatment. Since an untreated control group was not part of the study design, the magnitude of this improvement cannot be quantified.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1118-22"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1126
G Saruhan-Direskeneli
Objective: Associations with HLA-DRB alleles, implicated in the aetiopathogenesis of rheumatoid arthritis (RA), are found to be different in various ethnic groups. This study aimed to investigate DRB1 alleles in RA patients in Turkey.
Methods: The DRB region of the MHC was screened by polymerase chain reaction/sequence-specific oligonucleotide (PCR/SSO) hybridizations in 101 seropositive RA patients and compared with 101 healthy controls.
Results: Significant differences were in the frequencies of DRB1*0404 (12 vs 1, P = 0.003, OR = 13.5), *0401 (19 vs 4, P = 0.001, OR = 5.6) and *0408 (5 vs 0, P = 0.06, OR = 11.6) between RA patients and controls. The shared epitope (SE) was present in 70.2% of RA patients compared to 31.6% of controls (P < 0.0001, OR = 5.1). A double dose of SE was considerably more frequent in the RA group (21 vs 1, P < 0.0001, OR = 26.5).
Conclusion: These results support the reported positive association of RA with SE in seropositive patients in Turkey, and emphasize 'SE homozygosity' as the most strongly associated genetic susceptibility marker for RA.
目的:HLA-DRB等位基因与类风湿关节炎(RA)的发病机制相关,在不同民族中存在差异。本研究旨在调查土耳其RA患者的DRB1等位基因。方法:采用聚合酶链反应/序列特异性寡核苷酸(PCR/SSO)杂交技术筛选101例血清阳性RA患者MHC DRB区,并与101例健康对照进行比较。结果:RA患者与对照组DRB1*0404 (12 vs 1, P = 0.003, OR = 13.5)、*0401 (19 vs 4, P = 0.001, OR = 5.6)、*0408 (5 vs 0, P = 0.06, OR = 11.6)的频率差异有统计学意义。共有表位(SE)存在于70.2%的RA患者中,而对照组为31.6% (P < 0.0001, OR = 5.1)。双剂量SE在RA组中更为常见(21 vs 1, P < 0.0001, OR = 26.5)。结论:这些结果支持了土耳其血清阳性患者中RA与SE正相关的报道,并强调“SE纯合性”是RA最强烈相关的遗传易感性标志物。
{"title":"Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group.","authors":"G Saruhan-Direskeneli","doi":"10.1093/rheumatology/37.10.1126","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1126","url":null,"abstract":"<p><strong>Objective: </strong>Associations with HLA-DRB alleles, implicated in the aetiopathogenesis of rheumatoid arthritis (RA), are found to be different in various ethnic groups. This study aimed to investigate DRB1 alleles in RA patients in Turkey.</p><p><strong>Methods: </strong>The DRB region of the MHC was screened by polymerase chain reaction/sequence-specific oligonucleotide (PCR/SSO) hybridizations in 101 seropositive RA patients and compared with 101 healthy controls.</p><p><strong>Results: </strong>Significant differences were in the frequencies of DRB1*0404 (12 vs 1, P = 0.003, OR = 13.5), *0401 (19 vs 4, P = 0.001, OR = 5.6) and *0408 (5 vs 0, P = 0.06, OR = 11.6) between RA patients and controls. The shared epitope (SE) was present in 70.2% of RA patients compared to 31.6% of controls (P < 0.0001, OR = 5.1). A double dose of SE was considerably more frequent in the RA group (21 vs 1, P < 0.0001, OR = 26.5).</p><p><strong>Conclusion: </strong>These results support the reported positive association of RA with SE in seropositive patients in Turkey, and emphasize 'SE homozygosity' as the most strongly associated genetic susceptibility marker for RA.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1126-8"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1126","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1132
S M Mirsattari, C Power, A Fine, G S McGinn, S Ludwick, J M Canvin
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with neuropsychiatric lupus (NP-SLE) is rare. We report a case of SIADH associated with the new onset of SLE in an 88-yr-old female. The unique features of this case include the extreme age of onset of SLE presenting with neuropsychiatric manifestations and positive antiribosomal P antibody titres. Both the NP manifestations of SLE and SIADH were highly correlated with the SLE disease activity. This case illustrates a novel presentation of NP-SLE with SIADH which may develop due to antibody-mediated hypothalamic dysfunction.
{"title":"Neuropsychiatric systemic lupus erythematosus and the syndrome of inappropriate secretion of antidiuretic hormone: a case report with very late onset systemic lupus erythematosus.","authors":"S M Mirsattari, C Power, A Fine, G S McGinn, S Ludwick, J M Canvin","doi":"10.1093/rheumatology/37.10.1132","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1132","url":null,"abstract":"<p><p>The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with neuropsychiatric lupus (NP-SLE) is rare. We report a case of SIADH associated with the new onset of SLE in an 88-yr-old female. The unique features of this case include the extreme age of onset of SLE presenting with neuropsychiatric manifestations and positive antiribosomal P antibody titres. Both the NP manifestations of SLE and SIADH were highly correlated with the SLE disease activity. This case illustrates a novel presentation of NP-SLE with SIADH which may develop due to antibody-mediated hypothalamic dysfunction.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1132-4"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1132","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1140
S K Ming
{"title":"Binding feet, the living legacy of the Ching Dynasty (1644-1912), China.","authors":"S K Ming","doi":"10.1093/rheumatology/37.10.1140","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1140","url":null,"abstract":"","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1140-1"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1084
I E van der Horst-Bruinsma, I Speyer, H Visser, F C Breedveld, J M Hazes
Objective: Early arthritis patients referred to an Early Arthritis Clinic (EAC) (n = 233) were compared to 241 patients from the routine out-patient clinic with respect to lag time between the onset of symptoms and the visit to the rheumatologist, clinical presentation and the consistency of the diagnosis after 1 yr.
Results: The reduction in median lag time for the EAC patients was at least 3 months. An insidious onset of symptoms was found more often in the rheumatoid arthritis (RA) patients in the routine clinic. In 70% of all cases, a diagnosis could be made after 2 weeks and, if the clinical diagnosis was definite RA, this hardly changed during the following year. Early erosions were seen in 25% of RA patients and were associated with a positive rheumatoid factor (OR 2.08, 95% CI 0.95 4.59).
Conclusion: An early diagnosis of RA at the EAC is possible and reliable; the high frequency of erosions illustrates the need for early treatment.
目的:将233例早期关节炎患者(n = 233)与241例常规门诊患者(n = 241)进行比较,比较症状出现与风湿科医生就诊之间的滞后时间、临床表现和1年后诊断的一致性。结果:EAC患者的中位滞后时间减少了至少3个月。在常规临床中,发现类风湿性关节炎(RA)患者更常出现潜伏性症状。在所有病例中,70%的病例在2周后就能确诊,如果临床诊断为RA,这在接下来的一年中几乎没有改变。25%的RA患者出现早期糜坏,并与类风湿因子阳性相关(OR 2.08, 95% CI 0.95 4.59)。结论:EAC早期诊断RA是可能且可靠的;糜烂的高频率说明需要早期治疗。
{"title":"Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care.","authors":"I E van der Horst-Bruinsma, I Speyer, H Visser, F C Breedveld, J M Hazes","doi":"10.1093/rheumatology/37.10.1084","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1084","url":null,"abstract":"<p><strong>Objective: </strong>Early arthritis patients referred to an Early Arthritis Clinic (EAC) (n = 233) were compared to 241 patients from the routine out-patient clinic with respect to lag time between the onset of symptoms and the visit to the rheumatologist, clinical presentation and the consistency of the diagnosis after 1 yr.</p><p><strong>Results: </strong>The reduction in median lag time for the EAC patients was at least 3 months. An insidious onset of symptoms was found more often in the rheumatoid arthritis (RA) patients in the routine clinic. In 70% of all cases, a diagnosis could be made after 2 weeks and, if the clinical diagnosis was definite RA, this hardly changed during the following year. Early erosions were seen in 25% of RA patients and were associated with a positive rheumatoid factor (OR 2.08, 95% CI 0.95 4.59).</p><p><strong>Conclusion: </strong>An early diagnosis of RA at the EAC is possible and reliable; the high frequency of erosions illustrates the need for early treatment.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1084-8"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/rheumatology/37.10.1069
E Thomas, E M Hay, A Hajeer, A J Silman
Objective: Using the European Community (EC) criteria for classification Vitali et al. Arthritis Rheum 1993;36:340 7, we report the prevalence estimates of Sjogren's syndrome (SS) from a general population and present the first population data to assess the impact of the syndrome.
Methods: A cross-sectional population-based survey performed on 1000 adults, aged 18-75 yr, randomly selected from a population register. Responders to the initial postal phase were invited for an interview. The five criteria measured at interview were: (1) the reporting of subjective oral symptoms lasting for > 3 months; (2) the reporting of subjective ocular symptoms lasting for >3 months; (3) Schirmer-I test; (4) unstimulated salivary flow; (5) autoantibodies [Ro (SS-A), La (SS-B), rheumatoid factor (RF), antinuclear antibodies (ANA)]. SS was diagnosed if at least four of these five criteria were positive. The MOS Short-form 36 (SF-36), General Health Questionnaire (GHQ) and the Health and Fatigue Questionnaire (HFQ) were completed by subjects after the interview, and scores were compared between those with and without a diagnosis of SS.
Results: A total of 341 subjects completed both the postal questionnaire and home visit. A diagnosis of SS could be given to 13 subjects. After adjusting for the presence of possible bias due to non-response, our best estimate of the prevalence of SS in the study population was 33 per 1000 subjects (95% CI 22 44). The prevalence of the disorder was higher in females (38; 95% CI 27-52) and for those subjects aged > or = 55 yr (46; 95% CI 34-61). Those subjects diagnosed positively were more impaired for each of the eight dimensions of the SF-36 than those without a diagnosis, and also suffered from higher levels of depression and fatigue.
Conclusions: SS affects approximately 3-4% of adults and in the general population appears to be associated with a clinically significant impairment of a subject's health and well-being.
目的:利用欧共体(EC)标准对Vitali等人进行分类。风湿病1993;36:340,我们报告了普通人群中干燥综合征(SS)的患病率估计,并提出了第一个评估该综合征影响的人群数据。方法:对1000名年龄在18-75岁的成年人进行横断面人口调查,随机从人口登记册中选择。最初邮寄阶段的答复者被邀请进行面谈。访谈时测量的5项标准是:(1)报告主观口腔症状持续> 3个月;(2)报告主观眼部症状持续>3个月;(3) Schirmer-I检验;(4)无刺激唾液流;(5)自身抗体[Ro (SS-A), La (SS-B),类风湿因子(RF),抗核抗体(ANA)]。如果这五项标准中至少有四项为阳性,则诊断为SS。访谈结束后,对被试进行问卷调查(SF-36)、一般健康问卷(GHQ)和健康与疲劳问卷(HFQ),并比较被试和未被诊断为ss的被试的得分。结果:共341名被试完成了邮寄问卷和家访问卷。13例被诊断为SS。在调整了由于无反应而可能存在的偏倚后,我们对研究人群中SS患病率的最佳估计是每1000名受试者中有33名(95% CI 22.44)。女性的患病率更高(38;95% CI 27-52),对于年龄>或= 55岁的受试者(46;95% ci 34-61)。那些被诊断为阳性的受试者在SF-36的八个维度上都比那些没有被诊断为阳性的人受损更严重,而且抑郁和疲劳的程度也更高。结论:SS影响大约3-4%的成年人,在一般人群中似乎与受试者健康和福祉的临床显著损害有关。
{"title":"Sjögren's syndrome: a community-based study of prevalence and impact.","authors":"E Thomas, E M Hay, A Hajeer, A J Silman","doi":"10.1093/rheumatology/37.10.1069","DOIUrl":"https://doi.org/10.1093/rheumatology/37.10.1069","url":null,"abstract":"<p><strong>Objective: </strong>Using the European Community (EC) criteria for classification Vitali et al. Arthritis Rheum 1993;36:340 7, we report the prevalence estimates of Sjogren's syndrome (SS) from a general population and present the first population data to assess the impact of the syndrome.</p><p><strong>Methods: </strong>A cross-sectional population-based survey performed on 1000 adults, aged 18-75 yr, randomly selected from a population register. Responders to the initial postal phase were invited for an interview. The five criteria measured at interview were: (1) the reporting of subjective oral symptoms lasting for > 3 months; (2) the reporting of subjective ocular symptoms lasting for >3 months; (3) Schirmer-I test; (4) unstimulated salivary flow; (5) autoantibodies [Ro (SS-A), La (SS-B), rheumatoid factor (RF), antinuclear antibodies (ANA)]. SS was diagnosed if at least four of these five criteria were positive. The MOS Short-form 36 (SF-36), General Health Questionnaire (GHQ) and the Health and Fatigue Questionnaire (HFQ) were completed by subjects after the interview, and scores were compared between those with and without a diagnosis of SS.</p><p><strong>Results: </strong>A total of 341 subjects completed both the postal questionnaire and home visit. A diagnosis of SS could be given to 13 subjects. After adjusting for the presence of possible bias due to non-response, our best estimate of the prevalence of SS in the study population was 33 per 1000 subjects (95% CI 22 44). The prevalence of the disorder was higher in females (38; 95% CI 27-52) and for those subjects aged > or = 55 yr (46; 95% CI 34-61). Those subjects diagnosed positively were more impaired for each of the eight dimensions of the SF-36 than those without a diagnosis, and also suffered from higher levels of depression and fatigue.</p><p><strong>Conclusions: </strong>SS affects approximately 3-4% of adults and in the general population appears to be associated with a clinically significant impairment of a subject's health and well-being.</p>","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"37 10","pages":"1069-76"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/37.10.1069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20736969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1998-10-01DOI: 10.1093/RHEUMATOLOGY/37.10.1047
Ò. Miró, J. Casademont, J. Grau, D. Jarreta, A. Urbano-Márquez, F. Cardellach
OBJECTIVE Mitochondrial dysfunction in idiopathic inflammatory myopathies (IIM) remains a controversial issue. The aim of the present study was to investigate the correlation between histological abnormalities and the biochemical function of the skeletal muscle mitochondria from patients with dermatomyositis (DM). METHOD We evaluated 10 patients with a new diagnosis of DM and 15 healthy individuals, matched by age and gender. Muscle biopsy was routinely processed for histochemical studies and biochemical analysis of pure mitochondria. The percentages of ragged-red fibres (RRF), cytochrome c oxidase (COX)-negative fibres and succinic dehydrogenase (SDH) hyper-reactive fibres were calculated, oxygen utilization using different substrates was assessed polarographically, and enzymatic activity of individual complexes of the electron transport chain (ETC) and ATPase was measured spectrophotometrically. RESULTS We found an increased percentage of COX-negative and SDH hyper-reactive fibres in DM patients (0.82 and 1.82%, respectively) compared to controls (0.26 and 0.22%; P < 0.05 and P = 0.001, respectively); however, oxidation rates of different substrates and enzymatic activities of ETC and ATPase did not differ significantly between both groups. CONCLUSION The overall function of ETC from skeletal muscle mitochondria is not affected in DM.
目的特发性炎性肌病(IIM)的线粒体功能障碍仍然是一个有争议的问题。本研究旨在探讨皮肌炎(DM)患者骨骼肌线粒体的组织学异常与生化功能之间的相关性。方法我们评估了10例新诊断为糖尿病的患者和15例按年龄和性别匹配的健康人。肌肉活检常规处理纯线粒体的组织化学研究和生化分析。计算了粗红纤维(RRF)、细胞色素c氧化酶(COX)阴性纤维和琥珀酸脱氢酶(SDH)高反应纤维的百分比,极谱法评估了不同底物对氧的利用,分光光度法测定了电子传递链(ETC)和atp酶的单个配合物的酶活性。结果我们发现,与对照组(0.26%和0.22%)相比,DM患者中cox -阴性和SDH高反应纤维的比例(分别为0.82%和1.82%)有所增加;P < 0.05, P = 0.001);不同底物的氧化速率和ETC、atp酶活性在两组间无显著差异。结论糖尿病不影响骨骼肌线粒体ETC的整体功能。
{"title":"Histological and biochemical assessment of mitochondrial function in dermatomyositis.","authors":"Ò. Miró, J. Casademont, J. Grau, D. Jarreta, A. Urbano-Márquez, F. Cardellach","doi":"10.1093/RHEUMATOLOGY/37.10.1047","DOIUrl":"https://doi.org/10.1093/RHEUMATOLOGY/37.10.1047","url":null,"abstract":"OBJECTIVE\u0000Mitochondrial dysfunction in idiopathic inflammatory myopathies (IIM) remains a controversial issue. The aim of the present study was to investigate the correlation between histological abnormalities and the biochemical function of the skeletal muscle mitochondria from patients with dermatomyositis (DM).\u0000\u0000\u0000METHOD\u0000We evaluated 10 patients with a new diagnosis of DM and 15 healthy individuals, matched by age and gender. Muscle biopsy was routinely processed for histochemical studies and biochemical analysis of pure mitochondria. The percentages of ragged-red fibres (RRF), cytochrome c oxidase (COX)-negative fibres and succinic dehydrogenase (SDH) hyper-reactive fibres were calculated, oxygen utilization using different substrates was assessed polarographically, and enzymatic activity of individual complexes of the electron transport chain (ETC) and ATPase was measured spectrophotometrically.\u0000\u0000\u0000RESULTS\u0000We found an increased percentage of COX-negative and SDH hyper-reactive fibres in DM patients (0.82 and 1.82%, respectively) compared to controls (0.26 and 0.22%; P < 0.05 and P = 0.001, respectively); however, oxidation rates of different substrates and enzymatic activities of ETC and ATPase did not differ significantly between both groups.\u0000\u0000\u0000CONCLUSION\u0000The overall function of ETC from skeletal muscle mitochondria is not affected in DM.","PeriodicalId":9307,"journal":{"name":"British journal of rheumatology","volume":"51 1","pages":"1047-53"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90920603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}